{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:05:13Z","timestamp":1793397913527,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA042114"],"award-info":[{"award-number":["R01DA042114"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001450"],"award-info":[{"award-number":["UL1TR001450"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["K24DA038240"],"award-info":[{"award-number":["K24DA038240"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["K24AA031052"],"award-info":[{"award-number":["K24AA031052"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cannabis use disorder is particularly prevalent and impairing among young people, and evidence-based treatments are limited. Prior trials of N-acetylcysteine, added to contingency management as a platform behavioral intervention, yielded positive findings in youth but not in adults. This trial sought to rigorously evaluate whether N-acetylcysteine is efficacious in youth when not paired with a robust behavioral treatment platform. Treatment-seeking youth with cannabis use disorder (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009192, ages 14\u201321) were randomized to receive a double-blind 12-week course of oral N-acetylcysteine 1200\u2009mg or placebo twice daily; all received weekly medical management and brief behavioral counseling. The primary efficacy outcome was the proportion of negative urine cannabinoid tests during treatment, compared between groups. An array of self-report and urine testing measures were examined secondarily to assess cannabis use reduction and cessation outcomes. The N-acetylcysteine and placebo groups did not differ in proportion of negative urine cannabinoid tests (RR\u2009=\u20090.93, 95% CI\u2009=\u20090.53, 1.64;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.80) or self-reported cannabis abstinence (RR\u2009=\u20091.02, 95% CI\u2009=\u20090.63, 1.65;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.93) during treatment. The mean percentage of cannabis use days and grams of cannabis used per using day decreased over time during treatment but did not differ between groups. More N-acetylcysteine than placebo treated participants reported gastrointestinal adverse events (63\/98 versus 37\/94, \u03c7\n                    <jats:sup>2<\/jats:sup>\n                    <jats:sub>1<\/jats:sub>\n                    \u2009=\u200911.9\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001); adverse events were otherwise similar between groups. Findings indicate that N-acetylcysteine is not efficacious for youth cannabis use disorder when not paired with contingency management, highlighting the potentially crucial role of a robust behavioral treatment platform in facilitating prior positive efficacy findings with N-acetylcysteine.\n                  <\/jats:p>\n                  <jats:p>Trial Registration: Clinicaltrials.gov identifier NCT03055377<\/jats:p>","DOI":"10.1038\/s41386-025-02061-y","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T12:49:16Z","timestamp":1738759756000},"page":"731-738","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["N-acetylcysteine for youth cannabis use disorder: randomized controlled trial main findings"],"prefix":"10.1038","volume":"50","author":[{"given":"Kevin M.","family":"Gray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Tomko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3313-1579","authenticated-orcid":false,"given":"Nathaniel L.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9744-7818","authenticated-orcid":false,"given":"Erin A.","family":"McClure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee L.","family":"McRae-Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5994-6894","authenticated-orcid":false,"given":"Lindsay M.","family":"Squeglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"2061_CR1","doi-asserted-by":"publisher","first-page":"e072348","DOI":"10.1136\/bmj-2022-072348","volume":"382","author":"M Solmi","year":"2023","unstructured":"Solmi M, De Toffol M, Kim JY, Choi MJ, Stubbs B, Thompson T, et al. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ. 2023;382:e072348.","journal-title":"BMJ"},{"key":"2061_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.973988","volume":"13","author":"N Kaur","year":"2022","unstructured":"Kaur N, Bastien G, Gagnon L, Graham J, Mongeau-P\u00e9russe V, Bakouni H, et al. Variations of cannabis-related adverse mental health and addiction outcomes across adolescence and adulthood: a scoping review. Front Psychiatry. 2022;13:973988.","journal-title":"Front Psychiatry"},{"key":"2061_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jaac.2021.07.824","volume":"61","author":"WE Copeland","year":"2022","unstructured":"Copeland WE, Hill SN, Shanahan L. Adult psychiatric, substance, and functional outcomes of different definitions of early cannabis use. J Am Acad Child Adolesc Psychiatry. 2022;61:533\u201343.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2061_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1176\/appi.ajp.20231006","volume":"181","author":"JD Hinckley","year":"2024","unstructured":"Hinckley JD, Ferland JN, Hurd YL. The developmental trajectory to cannabis use disorder. Am J Psychiatry. 2024;181:353\u20138.","journal-title":"Am J Psychiatry"},{"key":"2061_CR5","first-page":"CD005336","volume":"2016","author":"PJ Gates","year":"2016","unstructured":"Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev. 2016;2016:CD005336.","journal-title":"Cochrane Database Syst Rev"},{"key":"2061_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.psc.2023.03.004","volume":"46","author":"ZW Adams","year":"2023","unstructured":"Adams ZW, Marriott BR, Hulvershorn LA, Hinckley JD. Treatment of adolescent cannabis use disorders. Psychiatr Clin North Am. 2023;46:775\u201388.","journal-title":"Psychiatr Clin North Am"},{"key":"2061_CR7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.7326\/M19-1105","volume":"172","author":"KK Kondo","year":"2020","unstructured":"Kondo KK, Morasco BJ, Nugent SM, et al. Pharmacotherapy for the treatment of cannabis use disorder: a systematic review. Ann Intern Med. 2020;172:398\u2013412.","journal-title":"Ann Intern Med"},{"key":"2061_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103295","volume":"97","author":"A Bahji","year":"2021","unstructured":"Bahji A, Meyyappan AC, Hawken ER, Tibbo PG. Pharmacotherapies for cannabis use disorder: a systematic review and network meta-analysis. Int J Drug Policy. 2021;97:103295.","journal-title":"Int J Drug Policy"},{"key":"2061_CR9","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s43440-021-00283-7","volume":"73","author":"I Smaga","year":"2021","unstructured":"Smaga I, Frankowska M, Filip M. N-acetylcysteine in substance use disorder: a lesson from preclinical and clinical research. Pharmacol Rep. 2021;73:1205\u201319.","journal-title":"Pharmacol Rep."},{"key":"2061_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40263-014-0142-x","volume":"28","author":"EA McClure","year":"2014","unstructured":"McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM. Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs. 2014;28:95\u2013106.","journal-title":"CNS Drugs"},{"key":"2061_CR11","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1176\/appi.ajp.2012.12010055","volume":"169","author":"KM Gray","year":"2012","unstructured":"Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012;169:805\u201312.","journal-title":"Am J Psychiatry"},{"key":"2061_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.drugalcdep.2017.04.020","volume":"177","author":"KM Gray","year":"2017","unstructured":"Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, et al. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017;177:249\u201357.","journal-title":"Drug Alcohol Depend"},{"key":"2061_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jsat.2010.08.010","volume":"40","author":"KM Gray","year":"2011","unstructured":"Gray KM, Carpenter MJ, Baker NL, Hartwell KJ, Lewis AL, Hiott DW, et al. Bupropion SR and contingency management for adolescent smoking cessation. J Subst Abuse Treat. 2011;40:77\u201386.","journal-title":"J Subst Abuse Treat"},{"key":"2061_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/00952990.2018.1437445","volume":"45","author":"RL Tomko","year":"2019","unstructured":"Tomko RL, Gray KM, Oppenheimer SR, Wahlquist AE, McClure EA. Using REDCap for ambulatory assessment: Implementation in a clinical trial for smoking cessation to augment in-person data collection. Am J Drug Alcohol Abuse. 2019;45:26\u201341.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"2061_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1037\/a0030992","volume":"28","author":"SM Robinson","year":"2014","unstructured":"Robinson SM, Sobell LC, Sobell MB, Leo GI. Reliability of the timeline followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav. 2014;28:154\u201362.","journal-title":"Psychol Addict Behav"},{"key":"2061_CR16","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/dta.2672","volume":"11","author":"T Duflot","year":"2019","unstructured":"Duflot T, Vasse M, Guillerme J, Schrapp A, Mory C, Imbert L, et al. Interest of adjusting urine cannabinoids to creatinine level to monitor cannabis cessation therapy in heavy smokers with psychiatric disorders. Drug Test Anal. 2019;11:1453\u20139.","journal-title":"Drug Test Anal"},{"key":"2061_CR17","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/dta.2576","volume":"11","author":"MA Huestis","year":"2019","unstructured":"Huestis MA, Blount BC, Milan DF, Newmeyer MN, Schroeder J, Smith ML. Correlation of creatinine- and specific gravity-normalized free and glucuronidated urine cannabinoid concentrations following smoked, vaporized, and oral cannabis in frequent and occasional cannabis users. Drug Test Anal. 2019;11:968\u201375.","journal-title":"Drug Test Anal"},{"key":"2061_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2017.09.035","volume":"182","author":"RL Tomko","year":"2018","unstructured":"Tomko RL, Baker NL, McClure EA, Sonne SC, McRae-Clark AL, Sherman BJ, et al. Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug Alcohol Depend. 2018;182:1\u20137.","journal-title":"Drug Alcohol Depend"},{"key":"2061_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1037\/1082-989X.2.1.64","volume":"2","author":"D Hedeker","year":"1997","unstructured":"Hedeker D, Gibbons RD. Application of random-effects pattern-mixture models for missing data in longitudinal studies. Psychol Methods. 1997;2:64\u201378.","journal-title":"Psychol Methods"},{"key":"2061_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.111096","volume":"256","author":"ME Cooke","year":"2024","unstructured":"Cooke ME, Knoll SJ, Streck JM, Potter K, Lamberth E, Rychik N, et al. Contingency management is associated with positive changes in attitudes and reductions in cannabis use even after discontinuation of incentives among non-treatment seeking youth. Drug Alcohol Depend. 2024;256:111096.","journal-title":"Drug Alcohol Depend"},{"key":"2061_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.drugalcdep.2016.08.622","volume":"167","author":"RM Schuster","year":"2016","unstructured":"Schuster RM, Hanly A, Gilman J, Budney A, Vandrey R, Evins AE. A contingency management method for 30-days abstinence in non-treatment seeking young adult cannabis users. Drug Alcohol Depend. 2016;167:199\u2013206.","journal-title":"Drug Alcohol Depend"},{"key":"2061_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2022.107552","volume":"138","author":"J Mennis","year":"2023","unstructured":"Mennis J, McKeon TP, Stahler GJ. Recreational cannabis legalization alters associations among cannabis use, perception of risk, and cannabis use disorder treatment for adolescents and young adults. Addict Behav. 2023;138:107552.","journal-title":"Addict Behav"},{"key":"2061_CR23","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/add.15253","volume":"116","author":"TP Freeman","year":"2021","unstructured":"Freeman TP, Craft S, Wilson J, Stylianou S, ElSohly M, Di Forti M, et al. Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. Addiction. 2021;116:1000\u201310.","journal-title":"Addiction"},{"key":"2061_CR24","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1080\/10826084.2024.2310500","volume":"59","author":"J Mennis","year":"2024","unstructured":"Mennis J, Stahler GJ, Coffman DL. Why are adolescent cannabis use disorder treatment admissions declining in the US? The mediated pathway of state treatment admissions rates before and after recreational cannabis legalization. Subst Use Misuse. 2024;59:962\u201370.","journal-title":"Subst Use Misuse"},{"key":"2061_CR25","doi-asserted-by":"publisher","unstructured":"Campbell G, Pocuca N, Newland G, Ellem R, Glasgow S, Dignan J, et al. Clinical profiles of people enrolling in alcohol and other drug treatment in Australia: Do youth differ from young adults and adults? Drug Alcohol Rev. 2024; https:\/\/doi.org\/10.1111\/dar.13925.","DOI":"10.1111\/dar.13925"},{"key":"2061_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2023.107845","volume":"148","author":"ME Patrick","year":"2024","unstructured":"Patrick ME, Peterson SJ, Terry-McElrath YM, Rogan SEB, Solberg MA. Trends in coping reasons for marijuana use among U.S. adolescents from 2016 to 2022. Addict Behav. 2024;148:107845.","journal-title":"Addict Behav"},{"key":"2061_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2023.100216","volume":"10","author":"C Vidal","year":"2024","unstructured":"Vidal C, Simon KM, Brooks C, White J, Hinckley JD. A systematic review of evidence on integrated management of psychiatric disorders in youth who use cannabis. Drug Alcohol Depend Rep. 2024;10:100216.","journal-title":"Drug Alcohol Depend Rep."},{"key":"2061_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2024.107635","volume":"144","author":"N Zaharakis","year":"2024","unstructured":"Zaharakis N, Coatsworth JD, Riggs NR, Radford A, Rayburn S, Mennis J, et al. Treating young adult cannabis use disorder with text message-delivered peer network counseling. Contemp Clin Trials. 2024;144:107635.","journal-title":"Contemp Clin Trials"},{"key":"2061_CR29","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1111\/acer.13829","volume":"42","author":"LA Ray","year":"2018","unstructured":"Ray LA, Bujarski S, Roche DJO, Magill M. Overcoming the \u201cvalley of death\u201d in medications development for alcohol use disorder. Alcohol Clin Exp Res. 2018;42:1612\u201322.","journal-title":"Alcohol Clin Exp Res"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02061-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02061-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02061-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T05:21:41Z","timestamp":1742188901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02061-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2061"],"URL":"https:\/\/doi.org\/10.1038\/s41386-025-02061-y","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KMG has provided consultation to Achieve Life Sciences, Indivior, and Jazz Pharmaceuticals, and he has received research support from Aelis Farma. ALM-C has provided consultation to Indivior and has received research support from PleoPharma. The other authors report no interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}